These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1863939)

  • 1. Citicoline in the treatment of Parkinson's disease.
    Martí Massó JF; Urtasun M
    Clin Ther; 1991; 13(2):239-42. PubMed ID: 1863939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citicoline in the treatment of Parkinson's disease.
    Eberhardt R; Birbamer G; Gerstenbrand F; Rainer E; Traegner H
    Clin Ther; 1990; 12(6):489-95. PubMed ID: 2289218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease.
    Cubells JM; Hernando C
    Clin Ther; 1988; 10(6):664-71. PubMed ID: 3064905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citicoline improves memory performance in elderly subjects.
    Alvarez XA; Laredo M; Corzo D; Fernández-Novoa L; Mouzo R; Perea JE; Daniele D; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1997 Apr; 19(3):201-10. PubMed ID: 9203170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reaction times during citicoline treatment].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(4):247-50. PubMed ID: 12400212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.
    Cho HJ; Kim YJ
    Methods Find Exp Clin Pharmacol; 2009 Apr; 31(3):171-6. PubMed ID: 19536360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.